BioSpace News Archive

Phase 1 trial evaluated the pharmacokinetics and safety of HBI-3000 when dosed with the strong CYP2D6 inhibitor, paroxetine.

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product life cycle, reported that its unique mix of active pharmaceutical ingredient sourcing and contract development and manufacturing services is helping to drive robust growth.

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that members of IMV’s executive management team will be participating in person at the H.C. Wainwright Global Investment Conference, which will be held in person and virtually May 23-26, 2022,

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2, open-label, proof-of-concept trial to evaluate its development-stage medicine daxdilimab (HZN-7734), a potentially first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7), to treat people with moderate-to-severe alopecia areata.

Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, announced the closing of the first tranche of €22 million as part of its Series D financing round that could reach up to €52 million in total.

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its soft-tissue portfolio with the launch of its Grappler™ Suture Anchor System.

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. (“KemPharm”).

Alzamend Neuro, Inc. today announced that it has submitted a Pre-IND (investigational new drug) meeting request for AL001 and supporting briefing documents to the U.S. Food and Drug Administration (“FDA”) for the treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder (“PTSD”).

Nuritas, a biotechnology company using AI to revolutionize the discovery of untapped, natural, bioactive peptides, announced it will build its North American headquarters in Connecticut, near Yale University.

Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022 and invites investors to participate via virtual one-on-one meetings or in-person in Miami, FL. Please see additional details below.